Not exact matches
Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600
genes and
offers a readout of patients
tumor mutational burden to help inform and assess immuno - oncology treatment.
«Identifying targets essential to cell survival in
tumor suppressor
genes has long been an investigational goal with the aim of
offering cancer - specific vulnerabilities for targeted therapy,» said Ronald DePinho, M.D., professor of Cancer Biology, MD Anderson president, and senior author for the Nature paper.
The study, published in Nature Genetics,
offers the possibility that targeting these processes, instead of single
genes, may provide new opportunities for treatment of Wilms
tumor.
«Biology of childhood brain
tumor subtypes
offers clues to precision treatments: Researchers reveal differences among
gene fusions in low - grade pediatric brain
tumors.»
Scientists have revealed the root of prostate cancers in individual men, discovering that despite huge genetic variety between
tumors they also share common
gene faults — insight that could
offer new treatment hopes, according to research published in Nature.
About 1,000 patients whose
tumor characteristics most closely match one of the 20 or so
gene - targeting drugs
offered in the study will be put into groups of about 30 patients to get that drug.